Effect of DAAs on Behavior of HCC in HCV Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03200171|
Recruitment Status : Completed
First Posted : June 27, 2017
Last Update Posted : July 21, 2021
|Condition or disease|
|Carcinoma, Hepatocellular Hepatitis C|
|Study Type :||Observational|
|Actual Enrollment :||300 participants|
|Official Title:||Effect of Direct Acting Antiviral Agents on Behavior of Hepatocellular Carcinoma and Overall Survival in Patients With Chronic Hepatitis C|
|Actual Study Start Date :||February 10, 2018|
|Actual Primary Completion Date :||June 19, 2021|
|Actual Study Completion Date :||July 19, 2021|
HCC patients who received DAAs for chronic HCV previously (either responders or not)
HCC patients who are naive to DAAs.
- Overall survival (OS) [ Time Frame: 6 months - 3 years ]he length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
- Behavior of hepatocellular carcinoma [ Time Frame: 6 months - 3 years ]Early recurrence, or rapid progression
- Progression-free survival (PFS) [ Time Frame: 6 months - 3 years ]The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Progression-free survival (PFS) will be measured by the Independent Radiological Review according to RECIST 1.1.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03200171
|Cairo, Egypt, 11651|
|National Hepatology and Tropical Medicine Research Institute|
|Principal Investigator:||Mohamed Alboraie, M.D.||Al-Azhar University|